Fox Chase Cancer Center News

PHILADELPHIA (December 2, 2021)—Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer. Gamitrinib is a first-in-class, mitochondrial-targeted inhibitor of the molecular chaperone heat shock protein-90 (HSP90) that works by inhibiting tumor cell metabolism and survival.

PHILADELPHIA (December 1, 2021)—Cihangir Duy, PhD, MS, an assistant professor in the Cancer Signaling and Epigenetics Program at Fox Chase Cancer Center, has been awarded a two-year V Scholar Award of $200,000. This grant will fund research into how certain acute myeloid leukemia (AML) cells can reinitiate leukemia after chemotherapy.

PHILADELPHIA (November 30, 2021)—Suzanne M. Miller, PhD, a professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has spearheaded a recent special edition of Translational Behavioral Medicine published today that summarizes several major lines of cancer prevention and control research and outlines future directions.

PHILADELPHIA (November 24, 2021)—Fox Chase Cancer Center is pleased to announce the hiring of Pamela Handelsman, PsyD, as an assistant professor in the Section of Psychiatry, where she will help patients cope with cancer across the entire care continuum, from initial diagnosis to end of life or survivorship.

PHILADELPHIA (November 22, 2021)—Jaye Gardiner, PhD, a postdoctoral researcher at Fox Chase Cancer Center, has received an inaugural Black in Cancer postdoctoral fellowship, which is funded by Emerald Foundation Inc. Gardiner will receive $75,000 annually for three years, money that will fund her research into pancreatic ductal adenocarcinoma (PDAC).  

PHILADELPHIA (November 22, 2021)—Fox Chase Cancer Center has begun using a new artificial intelligence-powered system called AlphaFold, which allows researchers to develop accurate predictions of how proteins fold into their final structures, making it a tool that could enhance the development of new drugs.

PHILADELPHIA (November 18, 2021)—In a recent study using liquid biopsies and tumor tissue biomarkers, researchers at Fox Chase Cancer Center found that PARP inhibitors and PD-1/PDL1 blocking immunotherapy could be considered an effective treatment in eligible inflammatory breast cancer patients.

PHILADELPHIA (November 15, 2021)— Gary Barbera and his Barbera Cares Ambassadors of Gary Barbera’s on the Boulevard, in partnership with State Representative Jared G. Solomon, will present a check for $10,000 to Fox Chase Cancer Center on November 22, money that will help improve the lives of patients and families affected by breast cancer.